Synopsis

Source of validity: Scientific
Rating (out of 5): 1

Monolaurin, a compound derived from lauric acid found in coconut oil, has been researched for its antiviral properties, including potential activity against enveloped viruses such as Epstein-Barr Virus (EBV). In vitro studies have shown that monolaurin can disrupt the lipid membranes of certain viruses, thereby inactivating them. This mechanism suggests a theoretical basis for its use against EBV, which is an enveloped herpesvirus. However, while laboratory evidence demonstrates monolaurin's antiviral effects against some viruses, there is a lack of direct clinical evidence or robust human trials specifically validating its effectiveness for treating or supporting EBV infection.

Most recommendations for using monolaurin in EBV are based on extrapolation from these laboratory findings and its established safety profile as a dietary supplement. There are anecdotal reports and some practitioner endorsements citing improvement in symptoms of chronic EBV or infectious mononucleosis, but these lack rigorous scientific validation. Currently, monolaurin’s use for EBV is not supported by high-quality clinical trials or authoritative guidelines. Thus, while there is a plausible scientific mechanism and some preliminary laboratory evidence, the overall strength of evidence supporting monolaurin for EBV is weak (rated 1 out of 5), and its use remains experimental rather than evidence-based.

More about monolaurin
More about Epstein Barr Virus

Other ingredients used for Epstein Barr Virus

Other health conditions supported by monolaurin

Products containing monolaurin